Displaying items by tag: Perrigo Co plc
Here is the MiBiz Growth Report for June 21, 2020.
Perrigo Co. plc has sold its generic prescription drug business to United Kingdom-based Rosemont Pharmaceuticals Ltd for $195 million in cash.
Perrigo Co. plc plans to enter the CBD market through a strategic investment and a long-term agreement with a Colorado supplier.
ALLEGAN — Higher consumer demand to treat symptoms of COVID-19 pushed Perrigo Co. plc to a 14-percent increase in sales growth for the first quarter.
ALLEGAN — Perrigo Co. plc recorded strong double-digit sales growth for the first quarter, as demand spiked for over-the-counter medications in March in the COVID-19 pandemic.
Here is the MiBiz growth report for March 1, 2020.
ALLEGAN — Perrigo Co. plc “hit on all cylinders” in the fourth quarter as sales growth picked up toward the end of 2019.
ALLEGAN — Perrigo Co. plc plans to buy the oral product line from Stamford, Conn.-based High Ridge Brands Inc., which filed for bankruptcy in December.
ALLEGAN — The transformation plan President and CEO Murray Kessler put in place last spring to return Perrigo Co. plc to revenue and earnings growth appears to have gained traction late in 2019, based on preliminary results for the fourth quarter.